Beta Carotene
FDA-approved product (capsule, oral), marketed as Solatene.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 0 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLNo approved indication recorded
ChEMBL records no approved indication for Beta Carotene. Its therapeutic class is shown instead.
- WHO therapeutic group
- Vitamin a, plain; Protectives against uv-radiation for systemic use
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
No supported pathogen reaches ≥40% AI-predicted activity for Beta Carotene, so it is not among the repurposing candidates. Its predictions are shown below.
AI-predicted activity
AI prediction · nothing measured- MRSA18.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli22.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae10.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis35.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Beta Carotene with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Dapiprazole HydrochlorideExisting use: Glaucoma, Mydriasis, Open-angle glaucoma44.0% AI-predicted activityagainst E. coliNo documented evidence found
- Anileridine PhosphateExisting use: Opioid anesthetics44.0% AI-predicted activityagainst E. coliNo documented evidence found
- RelugolixExisting use: Metastatic prostate cancer, Neoplasm, Prostate adenocarcinoma and 1 more43.9% AI-predicted activityagainst E. coli50+ registered studies
- ZuranoloneExisting use: Depressive disorder, Major depressive disorder, Postpartum depression43.8% AI-predicted activityagainst E. coli17 registered studies
- Rezafungin AcetateExisting use: Candidemia, Candidiasis, Candidiasis, Invasive43.8% AI-predicted activityagainst E. coli5 registered studies
- Naldemedine TosylateExisting use: Constipation, Constipation disorder43.7% AI-predicted activityagainst E. coli1 registered study
- Vorapaxar SulfateExisting use: Myocardial infarction, Peripheral arterial disease, Recurrent thrombophlebitis and 1 more43.7% AI-predicted activityagainst E. coli15 registered studies
- Asciminib HydrochlorideExisting use: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic myelogenous leukemia, Neoplasm43.7% AI-predicted activityagainst E. coliNo documented evidence found
- InavolisibExisting use: Breast cancer, Breast neoplasm43.7% AI-predicted activityagainst E. coli36 registered studies
- Landiolol HydrochlorideExisting use: Atrial fibrillation, Atrial flutter, Supraventricular tachycardia43.7% AI-predicted activityagainst E. coli6 registered studies
- AvacopanExisting use: Anti-neutrophil antibody associated vasculitis, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Granulomatosis with Polyangiitis and 1 more43.6% AI-predicted activityagainst E. coli26 registered studies
- Nefazodone HydrochlorideExisting use: Major depressive disorder43.6% AI-predicted activityagainst E. coli6 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Beta-carotene and Alpha-tocopherol Chemoprevention of Second Primary Malignancies in Head and Neck Cancer Patients
NCT00169845 · start 1994-10
Registered record
- Registry ID
- NCT00169845
- Conditions
- Neoplasms
- Interventions
- Alpha-Tocopherol and Beta-Carotene; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1994-10
- Completion
- 2018-03
- Enrolment
- 540
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNeoplasmsInterventionAlpha-Tocopherol and Beta-Carotene; PlaceboPhasePhase 3Registry statusCompletedPrimary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.
NCT00272428 · start 1994-10
Registered record
- Registry ID
- NCT00272428
- Conditions
- Healthy
- Interventions
- ascorbic acid, vitamin E, beta carotene, selenium, zinc
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1994-10
- Completion
- 2005-09
- Enrolment
- 13,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionascorbic acid, vitamin E, beta carotene, selenium, zincPhasePhase 3Registry statusCompletedArterial Disease Multifactorial Intervention Trial (ADMIT)
NCT00000539 · start 1992-09
Registered record
- Registry ID
- NCT00000539
- Conditions
- Arterial Occlusive Diseases; Cardiovascular Diseases; Heart Diseases; Vascular Diseases; Diabetes Mellitus
- Interventions
- niacin; pravastatin; beta-carotene; vitamin E; dietary supplements; vitamin C; warfarin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1992-09
- Completion
- 1999-03
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionArterial Occlusive Diseases; Cardiovascular Diseases; Heart Diseases; Vascular Diseases +1 moreInterventionniacin; pravastatin; beta-carotene; vitamin E +3 morePhasePhase 3Registry statusCompletedAge-Related Eye Disease Study (AREDS)
NCT00000145 · start 1990-09
Registered record
- Registry ID
- NCT00000145
- Conditions
- Macular Degeneration; Cataract; Lens Opacities
- Interventions
- Antioxidants; Zinc; Antioxidants and zinc
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1990-09
- Completion
- 2006-12
- Enrolment
- 4,757
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMacular Degeneration; Cataract; Lens OpacitiesInterventionAntioxidants; Zinc; Antioxidants and zincPhasePhase 3Registry statusCompletedCarotene and Retinol Efficacy Trial
NCT00712647 · start 1985-05
Registered record
- Registry ID
- NCT00712647
- Conditions
- Lung Cancer
- Interventions
- Beta Carotene and Retinol; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 1985-05
- Completion
- 2005-06
- Enrolment
- 18,314
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLung CancerInterventionBeta Carotene and Retinol; PlaceboPhasePhase 4Registry statusCompleted